Advanced Vision Therapies, Inc. Awarded Three Phase I SBIRs From NIH To Develop Therapies For Sight-Threatening Eye Diseases
10/19/2005 5:11:14 PM
Advanced Vision Therapies, Inc. (AVT) a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of major sight-threatening eye diseases, announced today that the National Institutes of Health (NIH) have awarded three independent Small Business Innovative Research (SBIR) grants totaling $687,000. This support will advance AVT's proprietary gene transfer technology toward clinical application for the treatment of prevalent eye diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
comments powered by